Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 13;12(6):964.
doi: 10.3390/jpm12060964.

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

Zachary Braunstein  1 , Miguel Ruiz  1 , Walter Hanel  2 , Polina Shindiapina  2 , John C Reneau  2 , Jonathan E Brammer  2
Affiliations
Review

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

Zachary Braunstein et al. J Pers Med. .

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.

Keywords: T cell; adult T-cell lymphoma; angioimmunoblastic T-cell lymphoma; leukemia; lymphoma; novel therapy; peripheral T-cell lymphoma; peripheral T-cell lymphoma not otherwise specified; refractory; relapsed; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Vose J., Armitage J., Weisenburger D., Project I.T.-C.L. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J. Clin. Oncol. 2008;26:4124–4130. doi: 10.1200/JCO.2008.16.4558. - DOI - PubMed
    1. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann. Oncol. 1998;9:717–720. doi: 10.1023/A:1008265532487. - DOI - PubMed
    1. Moskowitz A.J., Lunning M.A., Horwitz S.M. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636–2644. doi: 10.1182/blood-2013-12-516245. - DOI - PMC - PubMed
    1. Zain J.M. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am. J. Hematol. 2019;94:929–946. doi: 10.1002/ajh.25513. - DOI - PubMed

LinkOut - more resources